genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
CytomX Therapeutics
Drug Discovery
StockWatch: MacroGenics Shares Crater after Trial Deaths
Drug Discovery
StockWatch: Amgen Throws Its Weight Behind Obesity Drug
Cancer
Astellas, CytomX Launch $1.7B Cancer Immunotherapy Collaboration
Cancer
Pfizer Ends CytomX “Probody” Cancer Collaboration
Cancer
CytomX Wins $15M Milestone Payment from AbbVie for Cancer Probody–Drug Conjugate
Drug Discovery
BMS Pays CytomX $200M Upfront to Expand Probody Therapeutics Partnership
Drug Discovery
CytomX Wins $10M from BMS after Third Oncology Target Selected
Sponsored
Advertorial: OriGene Technologies
Cancer
CytomX, ImmunoGen Team Up to Develop Cancer-Fighting Probody-Drug Conjugates
Cancer
Pfizer, CytomX in Up To $635M Cancer Collaboration
1
2
Page 1 of 2
Scroll Up
Scroll Up
